Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Amneal Pharmaceuticals Inc (NY: AMRX ) 5.870 UNCHANGED Last Price Updated: 7:00 PM EST, Dec 26, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Amneal Pharmaceuticals Inc < Previous 1 2 3 4 5 6 7 Next > Amneal Receives FDA Approval for Leuprolide Acetate Injection November 02, 2022 From Amneal Pharmaceuticals, Inc. Via Business Wire Amneal Expands Leadership Team with Appointment of Senior Leaders in Quality and Regulatory October 31, 2022 From Amneal Pharmaceuticals, Inc. Via Business Wire Amneal to Report Third Quarter 2022 Results on November 4, 2022 October 06, 2022 From Amneal Pharmaceuticals, Inc. Via Business Wire Amneal Launches First Biosimilar with ALYMSYS® (bevacizumab-maly) in the United States October 03, 2022 From Amneal Pharmaceuticals, Inc. Via Business Wire Amneal Seeks FDA Approval For Its Parkinson's Candidate September 01, 2022 Via Benzinga Amneal Pharma Posts Mixed Q2 Earnings, Cuts Profit Outlook For 2022 August 05, 2022 Via Benzinga Recap: Amneal Pharmaceuticals Q2 Earnings August 05, 2022 Amneal Pharmaceuticals (NYSE:AMRX) reported its Q2 earnings results on Friday, August 5, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Via Benzinga Amneal Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer – Specialty September 06, 2022 From Amneal Pharmaceuticals, Inc. Via Business Wire 12 Health Care Stocks Moving In Wednesday's After-Market Session August 31, 2022 Gainers Via Benzinga Amneal Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson’s Disease August 31, 2022 From Amneal Pharmaceuticals, Inc. Via Business Wire Amneal supports Congress’ efforts to ensure essential medicines are Made in America August 22, 2022 From Amneal Pharmaceuticals, Inc. Via Business Wire Recap: Amneal Pharmaceuticals Q1 Earnings May 04, 2022 Amneal Pharmaceuticals (NYSE:AMRX) reported its Q1 earnings results on Wednesday, May 4, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Via Benzinga Amneal launches 4 new Generic products, including Vasopressin single-dose August 11, 2022 From Amneal Pharmaceuticals, Inc. Via Business Wire Stocks That Hit 52-Week Lows On Thursday August 11, 2022 On Thursday, 22 companies reached new 52-week lows. Via Benzinga Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases August 05, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Amneal Reports Second Quarter 2022 Financial Results August 05, 2022 From Amneal Pharmaceuticals, Inc. Via Business Wire Earnings Scheduled For August 5, 2022 August 05, 2022 Companies Reporting Before The Bell • Reservoir Media (NASDAQ:RSVR) is projected to report quarterly loss at $0.05 per share on revenue of $18.19 million. Via Benzinga Amneal Pharmaceuticals's Earnings: A Preview August 04, 2022 Amneal Pharmaceuticals (NYSE:AMRX) is set to give its latest quarterly earnings report on Friday, 2022-08-05. Here's what investors need to know before the announcement. Analysts estimate that Amneal... Via Benzinga Amneal Appoints Deborah M. Autor to Board of Directors August 03, 2022 From Amneal Pharmaceuticals, Inc. Via Business Wire Amneal to Report Second Quarter 2022 Results on August 5, 2022 July 08, 2022 From Amneal Pharmaceuticals, Inc. Via Business Wire Amneal Releases 2021 Corporate Responsibility Report Highlighting Continued ESG Impact and Integration June 07, 2022 From Amneal Pharmaceuticals, Inc. Via Business Wire Amneal Launches LYVISPAH® (baclofen) for Spasticity Related to Multiple Sclerosis and Other Spinal Cord Disorders June 01, 2022 From Amneal Pharmaceuticals, Inc. Via Business Wire Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk) May 27, 2022 From Amneal Pharmaceuticals, Inc. Via Business Wire Amneal to Participate at the 2022 Jefferies Healthcare Conference May 24, 2022 From Amneal Pharmaceuticals, Inc. Via Business Wire Amneal to Participate at Upcoming Investor Conferences in May May 13, 2022 From Amneal Pharmaceuticals, Inc. Via Business Wire The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints May 04, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours. Via Benzinga Amneal Reports First Quarter 2022 Financial Results May 04, 2022 From Amneal Pharmaceuticals, Inc. Via Business Wire Amneal Pharmaceuticals's Earnings Outlook May 03, 2022 Amneal Pharmaceuticals (NYSE:AMRX) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that... Via Benzinga 21 Stocks Moving in Monday's Pre-Market Session April 18, 2022 Gainers Mullen Automotive, Inc. (NASDAQ: MULN) shares rose 16.2% to $2.51 in pre-market trading. Mullen Automotive announced plans to begin construction for EV battery pack... Via Benzinga The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More April 14, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.